Gastroenterology Department, Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia.
School of Animal and Veterinary Sciences, University of Adelaide, Roseworthy, South Australia 5371, Australia.
Exp Biol Med (Maywood). 2020 Dec;245(18):1697-1707. doi: 10.1177/1535370220951105. Epub 2020 Sep 9.
Crohn's disease is a severe, incurable inflammatory bowel disease. Orally administered emu oil has demonstrated anti-inflammatory properties in previous models of gastrointestinal disease. We aimed to determine whether orally administered emu oil could attenuate disease in a mouse model of Crohn's-like colitis. Female ARC(s) mice (CD-1 equivalent, = 10/group) were intra-rectally administered water (120 μL) or trinitrobenzene sulfonic acid (TNBS; 3 mg in 50% ethanol; 120 μL bolus) on day 0. Mice were orally administered water (80 μL) or emu oil (80 μL or 160 μL) daily for five days and euthanized on day six. Bodyweight and disease activity were recorded daily. Colonoscopy, burrowing activity, facial grimace, histological parameters (damage severity, small intestinal villus height/crypt depth and colonic crypt depth), myeloperoxidase activity and intestinal permeability were assessed. < 0.05 was considered statistically significant. TNBS decreased bodyweight (days 1, 2, 4; < 0.05) and increased disease activity (days 1-6; < 0.01), compared to normal controls. Emu oil (80 μL) attenuated disease activity on days 5-6 ( < 0.05), although bodyweight loss was not significantly impacted ( > 0.05). Facial grimace and colonoscopy scores were significantly increased in TNBS-control mice; effects attenuated by both volumes of emu oil ( < 0.001). TNBS increased histological damage severity compared to normal controls ( < 0.05); an effect attenuated by 80 μL emu oil (proximal and distal colon; < 0.05) and 160 μL emu oil (distal colon; < 0.01). In the ileum, villus height and crypt depth were unaffected by TNBS or emu oil treatment compared to normal ( > 0.05). TNBS-induced distal colonic crypt lengthening was unaffected following emu oil administration ( > 0.05). Remaining parameters, including burrowing, myeloperoxidase activity and intestinal permeability, were unchanged across all treatment groups ( > 0.05). In normal mice, emu oil treatment did not significantly impact any parameter compared to normal controls. In conclusion, emu oil reduced overall disease severity and facial grimace scores in TNBS mice. These results suggest therapeutic potential for orally administered emu oil in the management of Crohn's disease.
克罗恩病是一种严重的、无法治愈的炎症性肠病。已证明口服鸸鹋油在以前的胃肠道疾病模型中具有抗炎作用。我们旨在确定口服鸸鹋油是否可以减轻类似克罗恩病的结肠炎小鼠模型中的疾病。雌性 ARC(s) 小鼠（CD-1 等效物，每组 10 只）在第 0 天经直肠给予水（120 μL）或三硝基苯磺酸（TNBS；3 mg 溶于 50%乙醇；120 μL 推注）。小鼠每天口服水（80 μL）或鸸鹋油（80 μL 或 160 μL）连续 5 天，并在第 6 天处死。记录体重和疾病活动度。进行结肠镜检查、挖掘活动、面部表情、组织学参数（损伤严重程度、小肠绒毛高度/隐窝深度和结肠隐窝深度）、髓过氧化物酶活性和肠道通透性评估。 < 0.05 被认为具有统计学意义。与正常对照组相比，TNBS 降低了体重（第 1、2、4 天； < 0.05）并增加了疾病活动度（第 1-6 天； < 0.01）。与 TNBS 对照组相比，鸸鹋油（80 μL）在第 5-6 天减轻了疾病活动度（ < 0.05），尽管体重减轻没有明显影响（ > 0.05）。在 TNBS 对照组中，面部表情和结肠镜评分显着增加；两种体积的鸸鹋油均减轻了这些影响（ < 0.001）。与正常对照组相比，TNBS 增加了组织学损伤严重程度（ < 0.05）；80 μL 鸸鹋油（近端和远端结肠； < 0.05）和 160 μL 鸸鹋油（远端结肠； < 0.01）减轻了这种影响。在回肠中，与正常对照组相比，TNBS 或鸸鹋油处理对绒毛高度和隐窝深度没有影响（ > 0.05）。给予鸸鹋油后，TNBS 诱导的远端结肠隐窝延长没有变化（ > 0.05）。在所有治疗组中，其余参数（包括挖掘、髓过氧化物酶活性和肠道通透性）均保持不变（ > 0.05）。在正常小鼠中，与正常对照组相比，鸸鹋油治疗对任何参数均无显着影响。总之，鸸鹋油减轻了 TNBS 小鼠的总体疾病严重程度和面部表情评分。这些结果表明，口服鸸鹋油在治疗克罗恩病方面具有潜在的治疗作用。
